Tirzepatide (Mounjaro): How the First Dual-Action Incretin Drug Compares for Type 2 Diabetes

This is a published drug review article summarizing evidence from the phase III SURPASS clinical trial program. The SURPASS trials evaluated tirzepatide as monotherapy and as add-on therapy to oral glucose-lowering medications and insulin across multiple randomized controlled trials in adults with type 2 diabetes.

Tirzepatide represents a paradigm shift in diabetes treatment by being the first approved drug to simultaneously activate both GIP and GLP-1 receptors. Its superiority over semaglutide — already considered one of the most effective GLP-1 drugs — in both glycemic control and weight loss establishes a new benchmark for incretin-based therapy. The dual mechanism suggests that combining incretin pathways may be more effective than targeting GLP-1 alone, opening a new chapter in metabolic disease treatment.

Tirzepatide has reshaped the metabolic drug landscape. By proving that dual incretin receptor activation outperforms GLP-1 agonism alone, it has validated a new therapeutic approach that pharmaceutical companies are now racing to build on. Beyond diabetes, tirzepatide has since gained approval for weight management (as Zepbound), and trials are exploring its use in heart failure, sleep apnea, and fatty liver disease. It represents the leading edge of a new generation of multi-target peptide therapeutics.

As a review article, this summarizes existing trial data rather than presenting new findings. The SURPASS trials compared tirzepatide to specific doses of competitors (semaglutide 1 mg, dulaglutide 0.75 mg), and comparisons at different doses might yield different results. Long-term safety data beyond the trial periods is still accumulating. The review focuses on type 2 diabetes; weight management approval data (SURMOUNT trials) is addressed separately.